![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 20-May-2013[ | E-mail |
Share ] Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD patients were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls. Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment. Foltynie and colleagues observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined. Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.
###
This study was funded by Cure Parkinson's Trust. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
TITLE: Exenatide and the treatment of patients with Parkinson's disease
AUTHOR CONTACT:
Thomas Foltynie
UCL Institute of Neurology, London, GBR
Phone: 44 203 448 8726; E-mail: T.Foltynie@ucl.ac.uk
View this article at: http://www.jci.org/articles/view/68295?key=424690bda975bb0c7d68
ACCOMPANYING COMMENTARY
TITLE: A new approach to disease-modifying drug trials in Parkinson's disease
AUTHOR CONTACT:
Patrik Brundin
Van Andel Institute, Grand Rapids, MI, USA
Phone: 616-234-5684; E-mail: Patrik.Brundin@vai.org
View this article at: http://www.jci.org/articles/view/69690?key=5b7b3c4b320e2bc2a0e5
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 20-May-2013[ | E-mail |
Share ] Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the progression of the disease. In this issue of the Journal of Clinical Investigation, Dr. Thomas Foltynie and colleagues at the National Hospital for Neurology and Neurosurgery in London investigated the use of a drug approved for diabetes care, Exenatide, in PD patients. PD patients were divided into two groups: 20 patients received Exenatide injections for 12 months, while the other group of 24 patients served as controls. Due to high manufacturing costs, the control group did not receive placebo injections and the patients were aware of their group assignment. Foltynie and colleagues observed that Exenatide was well tolerated. After one year of treatment patients receiving Exenatide displayed improved cognitive ability and motor skills, while control patients declined. Though this trial cannot rule out a placebo effect, the study suggests that Exenatide may improved motor function in PD patients and provides a strong rationale for conducting a larger, blinded study to determine the effectiveness of Exenatide in PD. In the accompanying commentary, Roger Barker (University of Cambridge), Mark Stacy (Duke University) and Patrik Brundin (Van Andel Institute) discuss the novel, cost-saving clinical trial design used in this study.
###
This study was funded by Cure Parkinson's Trust. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
TITLE: Exenatide and the treatment of patients with Parkinson's disease
AUTHOR CONTACT:
Thomas Foltynie
UCL Institute of Neurology, London, GBR
Phone: 44 203 448 8726; E-mail: T.Foltynie@ucl.ac.uk
View this article at: http://www.jci.org/articles/view/68295?key=424690bda975bb0c7d68
ACCOMPANYING COMMENTARY
TITLE: A new approach to disease-modifying drug trials in Parkinson's disease
AUTHOR CONTACT:
Patrik Brundin
Van Andel Institute, Grand Rapids, MI, USA
Phone: 616-234-5684; E-mail: Patrik.Brundin@vai.org
View this article at: http://www.jci.org/articles/view/69690?key=5b7b3c4b320e2bc2a0e5
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-05/joci-ddt051313.php
big east tournament 2012 solar storm spanx solar flares mary j blige gcb patricia heaton
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.